DrugPatentWatch has published a list of research papers citing DrugPatentWatch at https://www.drugpatentwatch.com/citations/ Explore the Growing Body of Research Citing DrugPatentWatch […]
See How Researchers are Using DrugPatentWatch: Read Post »
The Economic Architecture of Generic Drug Markets Generic drugs are not simplified copies. They are pharmaceutical products held to the
A deep-dive reference on pipeline productivity, attrition economics, open innovation architecture, AI-driven discovery, and patent lifecycle strategy for biopharma decision-makers.
Reviving a Pharmaceutical R&D Pipeline: The Complete Technical, IP, and Strategic Guide Read Post »
Generic drug development is a high-stakes capital allocation decision disguised as a regulatory exercise. The Abbreviated New Drug Application (ANDA)
Pharmaceutical executives spend billions building patent portfolios. Analysts spend months modeling their worth. And yet the conversation about what actually
Drug Patent Value: The Indicators That Actually Predict Pharma Market Power Read Post »
A drug patent is not a legal formality. It is the financial architecture that determines whether a company can fund
1. The Problem: Eroom’s Law and the Monolith Trap The Economics Are Getting Worse, Not Better Drug development has gotten
Snackable AI in Pharma: The Modular Architecture That Beats Eroom’s Law Read Post »
1. The Effective Patent Life Problem: Numbers, Not Theory Here is what the 20-year patent term looks like from inside
Key Takeaways (Executive Summary) Part I: What Drug Repurposing Actually Is — and Why the Economics Changed Defining the Strategy:
Sign in or create a free account to read this DrugPatentWatch article
